Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;73(9):893-905.
doi: 10.1007/s40265-013-0059-6.

HIV-associated neurocognitive disorders: perspective on management strategies

Linda Nabha  1 , Lan Duong, Joseph Timpone
Affiliations
Review

HIV-associated neurocognitive disorders: perspective on management strategies

Linda Nabha et al. Drugs. 2013 Jun.

Abstract

Potent combination antiretroviral therapy (ART) has resulted in dramatic improvements in AIDS-associated morbidity and mortality. Although combination ART has resulted in a significant reduction in HIV-associated dementia, the most severe of the HIV-associated neurocognitive disorders (HAND), the overall prevalence of HAND among this population is estimated at 40%. It has been recognized that the central nervous system (CNS) serves as a reservoir for HIV, and neuronal damage begins at the time of acute infection and persists due to chronic infection of microglial and perivascular macrophages. Although combination ART has resulted in virologic control in the plasma compartment, virologic breakthrough can potentially ensue within the CNS compartment due to limited ART drug exposure. The purpose of this review is to discuss the definition, clinical spectrum, and risk factors associated with HAND, review the pathogenesis of HAND, and address the pharmacologic challenges associated with ART drug exposure in the CNS compartment.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Organization WH HIV/AIDS: Fact sheet. 2012 Nov; [cited 2013 2013 Jan 9]; Available from: http://www.who.int/mediacentre/factsheets/fs360/en/index.html.
    1. Cysique LA, Bain MP, Brew BJ, Murray JM. The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future. Sex Health. 2011 Dec;8(4):541–50. - PubMed
    1. Letendre S, McClernon D, Ellis R, Munoz-Moreno J, Way L, Franklin D, Heaton R, Grant I. Persistent HIV in the central nervous system during treatment is associated with worse antiretroviral therapy penetration and cognitive impairment. 16th Conference on Retroviruses and Opportunistic Infections; 2009.
    1. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 Feb;17(1):3–16. - PMC - PubMed
    1. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010 Mar 1;50(5):773–8. - PubMed

Substances